Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07762170
Success Rates and Safety of Steroid Injections in Managing Spinal and Sacro-Iliac Pain (CORTisone Injection Spine Study)Igor Wilderman. MDRecruitingPhase 4
NCT07762170Recruiting
Phase 4
Success Rates and Safety of Steroid Injections in Managing Spinal and Sacro-Ilia...Igor Wilderman. MD
NCT07763548
A Novel Two-Step Dosing Induction Strategy (The Propofol Challenge Test) to Minimize Propofol Injection PainErasme University HospitalNot Yet RecruitingPhase 4
NCT07763548Not Yet Recruiting
Phase 4
A Novel Two-Step Dosing Induction Strategy (The Propofol Challenge Test) to Mini...Erasme University Hospita...
NCT07764003
A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHsHangzhou Highlightll Pharmaceutical Co., LtdNot Yet RecruitingPhase 2
NCT07764003Not Yet Recruiting
Phase 2
A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Re...Hangzhou Highlightll Phar...
NCT07763171
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal AdenocarcinomaGruppo Oncologico del Nord-OvestNot Yet RecruitingPhase 3
NCT07763171Not Yet Recruiting
Phase 3
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-neg...Gruppo Oncologico del Nor...
NCT07763431
Home-Use Dual-Light Antibacterial Photodynamic Therapy for Peri-Implant Mucositis in Full-Arch Implant ProsthesesUniversity of Medicine and Pharmacy at Ho Chi Minh CityNot Yet RecruitingNot Applicable
NCT07763431Not Yet Recruiting
Not Applicable
Home-Use Dual-Light Antibacterial Photodynamic Therapy for Peri-Implant Mucositi...University of Medicine an...
NCT07762209
Papilozumib Vaginal Gel for Exocervical Mucosal Restoration in Women With HPVAdknoma Health ResearchNot Yet RecruitingNot Applicable
NCT07762209Not Yet Recruiting
Not Applicable
Papilozumib Vaginal Gel for Exocervical Mucosal Restoration in Women With HPVAdknoma Health Research
NCT07763184
mNGS for IFD in Patients With Hematological MalignanciesNanfang Hospital, Southern Medical UniversityNot Yet Recruiting
NCT07763184Not Yet Recruiting
—
mNGS for IFD in Patients With Hematological MalignanciesNanfang Hospital, Souther...
NCT07763067
Acceptability and Outcomes of an Online Parent-Mediated Intervention for Young Autistic ChildrenHerguner Therapy Private ClinicCompletedNot Applicable
NCT07763067Completed
Not Applicable
Acceptability and Outcomes of an Online Parent-Mediated Intervention for Young A...Herguner Therapy Private...
NCT07762261
Impact of Generative AI on University Students' Learning Processes and Critical ThinkingAtaturk UniversityNot Yet RecruitingNot Applicable
NCT07762261Not Yet Recruiting
Not Applicable
Impact of Generative AI on University Students' Learning Processes and Critical...Ataturk University
NCT07763262
Autologous Nanofat Injection for Treatment of Stable VitiligoBenha UniversityCompletedNot Applicable
NCT07763262Completed
Not Applicable
Autologous Nanofat Injection for Treatment of Stable VitiligoBenha University
NCT07763704
The Impact of Tonsillectomy Techniques on Secondary Tonsillectomy BleedingAssiut UniversityNot Yet Recruiting
NCT07763704Not Yet Recruiting
—
The Impact of Tonsillectomy Techniques on Secondary Tonsillectomy BleedingAssiut University
NCT07762872
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSDChifeng Municipal HospitalRecruiting
NCT07762872Recruiting
—
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in...Chifeng Municipal Hospita...
NCT07762027
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus InfectionAssembly BiosciencesNot Yet RecruitingPhase 2
NCT07762027Not Yet Recruiting
Phase 2
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Part...Assembly Biosciences
NCT07764263
Contextualizing Care for Patients With a Serious IllnessRadboud University Medical CenterCompletedNot Applicable
NCT07764263Completed
Not Applicable
Contextualizing Care for Patients With a Serious IllnessRadboud University Medica...
NCT07762898
Sedentary Behavior Intervention for Older Adults With Coronary Heart Disease and FrailtyGansu University of Chinese MedicineNot Yet RecruitingNot Applicable
NCT07762898Not Yet Recruiting
Not Applicable
Sedentary Behavior Intervention for Older Adults With Coronary Heart Disease and...Gansu University of Chine...
NCT07762690
Mechanism-Based Cervical Rehabilitation for Chronic MigraineBeni-Suef UniversityNot Yet RecruitingNot Applicable
NCT07762690Not Yet Recruiting
Not Applicable
Mechanism-Based Cervical Rehabilitation for Chronic MigraineBeni-Suef University
NCT07763314
Trends and Short-term Outcomes of Surgically Resected Early-onset Colorectal Cancer in Switzerland Between 2003 and 2022Cantonal Hospital of St. GallenCompleted
NCT07763314Completed
—
Trends and Short-term Outcomes of Surgically Resected Early-onset Colorectal Can...Cantonal Hospital of St....
NCT07761962
Laser Assisted Pulpotomy Versus MTA Pulpotomy in Permanent Teeth With Irreversible PulpitisKing Abdullah University HospitalActive Not RecruitingNot Applicable
NCT07761962Active Not Recruiting
Not Applicable
Laser Assisted Pulpotomy Versus MTA Pulpotomy in Permanent Teeth With Irreversib...King Abdullah University...
NCT07762703
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762703Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metasta...BreakBio Corp
Result Breakdown
Not yet recruiting12 (60%)
Completed5 (25%)
Recruiting2 (10%)
Active, not recruiting1 (5%)
not_applicable10 (50%)
Not Specified4 (20%)
Phase 42 (10%)
Phase 22 (10%)
Phase 31 (5%)
Phase 11 (5%)